Bright Minds Biosciences INC. (DRUG) — SEC Filings

Overview

Bright Minds Biosciences INC. (DRUG) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 17, 2025: Bright Minds Biosciences Inc. filed a Form 6-K on November 17, 2025, incorporating a news release dated November 17, 2025. This filing is related to their registration statements on Form F-3 (File No. 333-284694 and 333-289851). The company's principal executive office is located at 19 Vestry Street

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 2 bullish, 33 neutral. The dominant filing sentiment for Bright Minds Biosciences INC. is neutral.

Filing Type Overview

Bright Minds Biosciences INC. (DRUG) has filed 24 6-K, 1 20-F, 6 SC 13G, 2 SC 13G/A, 1 SC 13D/A, 1 SC 13D with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (35)

• Bright Minds Biosciences Files 6-K, Incorporates News Release — 6-K · Nov 17, 2025 Risk: low
  Bright Minds Biosciences Inc. filed a Form 6-K on November 17, 2025, incorporating a news release dated November 17, 2025. This filing is related to their regis
• Bright Minds Biosciences Files 6-K Report — 6-K · Nov 7, 2025 Risk: low
  Bright Minds Biosciences Inc. filed a Form 6-K on November 7, 2025, reporting for the month of November 2025. The filing includes a news release dated November
• Bright Minds Biosciences: BMB-201 Outperforms Sumatriptan — 6-K · Sep 5, 2025 Risk: medium
  Bright Minds Biosciences Inc. filed a Form 6-K on September 5, 2025, reporting a news release dated September 4, 2025. The news release announced that their dru
• Bright Minds Biosciences Files Q3 Financials — 6-K · Aug 15, 2025 Risk: medium
  Bright Minds Biosciences Inc. filed a Form 6-K on August 15, 2025, reporting its Condensed Interim Consolidated Financial Statements for the nine months ended J
• Bright Minds Biosciences Files Q2 2025 Financial Update — 6-K · Aug 11, 2025 Risk: medium
  Bright Minds Biosciences Inc. filed a Form 6-K on August 11, 2025, reporting its Condensed Interim Consolidated Financial Statements for the six months ended Ma
• Bright Minds Biosciences to Present at Jefferies Healthcare Conference — 6-K · May 28, 2025 Risk: low
  Bright Minds Biosciences Inc. announced on May 28, 2025, that it will present at the 2025 Jefferies Global Healthcare Conference. The company, located at 19 Ves
• Bright Minds Biosciences Hosts Absence Epilepsy R&D Day — 6-K · May 21, 2025 Risk: low
  Bright Minds Biosciences Inc. announced on May 20, 2025, that it will host a virtual R&D Day focused on absence epilepsy. The event will feature presentations f
• Bright Minds Biosciences Reports Positive Study Findings — 6-K · May 14, 2025 Risk: medium
  Bright Minds Biosciences Inc. filed a Form 6-K on May 14, 2025, reporting on a news release dated May 13, 2025. The news release details positive findings from
• Bright Minds Biosciences Files 6-K, Incorporates News Release — 6-K · Apr 29, 2025 Risk: low
  Bright Minds Biosciences Inc. filed a Form 6-K on April 29, 2025, incorporating a news release dated April 28, 2025. This filing is related to their registratio
• Bright Minds Biosciences Files 6-K, Incorporates F-3 Registration — 6-K · Mar 5, 2025 Risk: low
  Bright Minds Biosciences Inc. filed a Form 6-K on March 5, 2025, incorporating a news release dated March 4, 2025. This filing is related to their registration
• Bright Minds Biosciences to Present at March Healthcare Conferences — 6-K · Feb 24, 2025 Risk: low
  Bright Minds Biosciences Inc. announced on February 24, 2025, that it will participate in three healthcare conferences in March 2025. These conferences include
• Bright Minds Biosciences Files Q1 Financial Update — 6-K · Feb 14, 2025 Risk: medium
  Bright Minds Biosciences Inc. filed a Form 6-K on February 14, 2025, reporting its Condensed Interim Consolidated Financial Statements for the three months ende
• Bright Minds Biosciences Appoints New Chief Medical Officer — 6-K · Jan 8, 2025 Risk: low
  Bright Minds Biosciences Inc. announced on January 7, 2025, the appointment of Stephen Collins, M.D., Ph.D., as its new Chief Medical Officer. Dr. Collins bring
• Bright Minds Biosciences Files 20-F Annual Report — 20-F · Dec 31, 2024 Risk: medium
  Bright Minds Biosciences Inc. filed its annual 20-F report for the period ending September 30, 2024. The company, incorporated in A1 and headquartered at 19 Ves
• Bright Minds Biosciences to Present at AES 2024 Meeting — 6-K · Nov 21, 2024 Risk: low
  Bright Minds Biosciences Inc. announced on November 21, 2024, that it will present data at the American Epilepsy Society 2024 Annual Meeting. The company, locat
• SC 13G Filing — SC 13G · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 6, 2024
• Bright Minds Biosciences Closes $35M Private Placement — 6-K · Nov 5, 2024 Risk: medium
  Bright Minds Biosciences Inc. announced on November 4, 2024, the closing of a US$35 million non-brokered private placement. The company, headquartered at 19 Ves
• SC 13G Filing — SC 13G · Oct 25, 2024
• SC 13G Filing — SC 13G · Oct 23, 2024
• SC 13G Filing — SC 13G · Oct 23, 2024
• SC 13G/A Filing — SC 13G/A · Oct 22, 2024
• SC 13G Filing — SC 13G · Oct 22, 2024
• Bright Minds Biosciences Partners with Firefly Neuroscience — 6-K · Oct 21, 2024 Risk: medium
  Bright Minds Biosciences Inc. announced on October 21, 2024, a collaboration with Firefly Neuroscience following the BREAKTHROUGH study. The specific details of
• Bright Minds Biosciences Files 6-K with Redacted News Release — 6-K · Oct 18, 2024 Risk: medium
  Bright Minds Biosciences Inc. filed a Form 6-K on October 18, 2024, to submit a news release dated October 18, 2024. The news release was embargoed against dist
• SC 13G Filing — SC 13G · Oct 16, 2024
• Bright Minds Biosciences Files 6-K Report — 6-K · Oct 16, 2024 Risk: low
  Bright Minds Biosciences Inc. filed a Form 6-K on October 16, 2024, reporting for the month of October 2024. The filing includes a news release dated October 15
• Bright Minds Biosciences Files 6-K Report — 6-K · Oct 16, 2024 Risk: low
  Bright Minds Biosciences Inc. filed a Form 6-K on October 16, 2024, to report information for the month of October 2024. The filing includes a press release dat
• Bright Minds Biosciences Files 6-K with Press Release — 6-K · Oct 3, 2024 Risk: low
  Bright Minds Biosciences Inc. filed a Form 6-K on October 3, 2024, to report information as a foreign private issuer. The filing includes a press release dated
• Bright Minds Biosciences Files 6-K — 6-K · Sep 12, 2024 Risk: low
  Bright Minds Biosciences Inc. filed a Form 6-K on September 12, 2024, to report a news release dated the same day. The filing does not contain specific financia
• Bright Minds Biosciences Files 6-K with Financials — 6-K · Aug 15, 2024 Risk: medium
  Bright Minds Biosciences Inc. filed a Form 6-K on August 15, 2024, reporting its condensed interim consolidated financial statements for the nine months ended J
• Bright Minds Biosciences Files 6-K with Meeting Notices — 6-K · May 17, 2024 Risk: low
  Bright Minds Biosciences Inc. filed a Form 6-K on May 17, 2024, reporting information for the month of March 2024. The filing includes a Notice of Meeting and R
• Ian McDonald Amends BRIGHT MINDS BIOSCIENCES Stake Filing — SC 13D/A · Feb 26, 2024 Risk: low
  Ian McDonald, a significant shareholder, filed an amendment to his Schedule 13D for BRIGHT MINDS BIOSCIENCES INC. (NASDAQ: BMBI) on February 26, 2024. This amen
• Bright Minds Biosciences Files Q4 2023 Interim Financials — 6-K · Feb 13, 2024 Risk: low
  BRIGHT MINDS BIOSCIENCES INC., a foreign private issuer, filed a Form 6-K on February 13, 2024, reporting its Condensed Interim Consolidated Financial Statement
• Ian McDonald Files SC 13D on Bright Minds Biosciences Stock — SC 13D · Jan 18, 2024
  Ian McDonald, an individual, has filed an SC 13D on January 18, 2024, disclosing his ownership of common stock in BRIGHT MINDS BIOSCIENCES INC. The filing indic

Risk Profile

Risk Assessment: Of DRUG's 26 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Ryan Cheung
• Dr. Elaine Wyllie
• Dr. Michael Chez
• Stephen Collins, M.D., Ph.D.
• Ian McDonald

Top Tags

news-release (9) · sec-filing (5) · filing (4) · reporting (4) · biotech (4) · financials (3) · registration-statement (2) · interim-results (2) · interim-financials (2) · conference-presentation (2)

Key Numbers

• SEC File Number: 001-40997 — Identifies the company's filing history with the SEC
• Registration Statement File Number: 333-284694 — Related to prior F-3 filing
• Reporting Period: Q2 2025 — Financials cover the second quarter ending March 31, 2025.
• Form F-3 File Number: 333-284694 — Relates to the company's registration statement for potential securities offerings.
• Fiscal Year End: 20240930 — The period covered by the 20-F filing.
• Previous Fiscal Year End: 20230930 — Provides comparative financial data.
• Private Placement: $35 million — Capital raised by Bright Minds Biosciences Inc.
• Form Type: 6-K — Standard SEC filing for foreign private issuers
• Financial Statements: N/A — The filing indicates the presence of Condensed Interim Consolidated Financial Statements for Q4 2023 and Q4 2022, but specific dollar amounts are not provided in this excerpt.

Related Companies

BMBS · BRIGHT MINDS BIOSCIENCES INC.

Frequently Asked Questions